{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:39:10Z","timestamp":1786451950484,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.urolonc.2011.09.008","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T23:18:16Z","timestamp":1323559096000},"page":"1343-1349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Takehiro","family":"Sejima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Isoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2011.09.008_bib1","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2011.09.008_bib2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","article-title":"Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family","volume":"75","author":"Suda","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2011.09.008_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.iy.10.040192.001411","article-title":"Apoptosis and programmed cell death in immunity","volume":"10","author":"Cohen","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/370650a0","article-title":"Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways","volume":"370","author":"Lowin","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2011.09.008_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0167-5699(98)01435-2","article-title":"Where have all the T cells gone? Mechanisms of immune evasion by tumors","volume":"20","author":"Finke","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.urolonc.2011.09.008_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002620000154","article-title":"Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient","volume":"49","author":"Real","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2011.09.008_bib7","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1158\/0008-5472.CAN-09-0685","article-title":"Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity","volume":"69","author":"Shanker","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.09.008_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.ju.0000146713.50673.e5","article-title":"C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy","volume":"173","author":"Casamassima","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2006.06497.x","article-title":"Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma","volume":"99","author":"Komai","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2011.09.008_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jso.20329","article-title":"Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer","volume":"91","author":"Walsh","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000127412","article-title":"The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer","volume":"73","author":"Yamanaka","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2011.09.008_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pretreatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2011.09.008_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00262-005-0680-7","article-title":"Tumor counterattack: Fact or fiction?","volume":"54","author":"Igney","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2011.09.008_bib14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00000421-199708000-00020","article-title":"Spontaneous regression of metastatic renal cancer: Case report and literature review","volume":"20","author":"Lokich","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1442-2042.2003.00662.x","article-title":"Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma","volume":"10","author":"Sejima","year":"2003","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","article-title":"Improving T cell therapy for cancer","volume":"25","author":"Leen","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","article-title":"Lymphocyte-mediated cytotoxicity","volume":"20","author":"Russell","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.humpath.2007.06.010","article-title":"The \u201cFas counterattack\u201d is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability","volume":"39","author":"Houston","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4161\/cc.5.3.2413","article-title":"Fas ligand promotes tumor immune evasion of colon cancer in vivo","volume":"5","author":"Ryan","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.urolonc.2011.09.008_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.184.3.1075","article-title":"The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand","volume":"184","author":"O'Connell","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2011.09.008_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.2042","article-title":"Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: An active mode of immune evasion in colon cancer","volume":"85","author":"Song","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2011.09.008_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/35037728","article-title":"CD95's deadly mission in the immune system","volume":"407","author":"Krammer","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2011.09.008_bib24","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.4049\/jimmunol.160.11.5669","article-title":"The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma","volume":"160","author":"Bennett","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib25","first-page":"1007","article-title":"Human lung carcinomas express Fas ligand","volume":"57","author":"Niehans","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2011.09.008_bib26","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1158\/1078-0432.CCR-04-1111","article-title":"Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: No in vivo effect of Fas ligand tumor counterattack","volume":"10","author":"Donskov","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2011.09.008_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2011.09.008_bib28","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts\u2014rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.urolonc.2011.09.008_bib29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.juro.2010.05.028","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma","volume":"184","author":"Ohno","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2011.09.008_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/sj.bjc.6600768","article-title":"Metastatic renal carcinoma comprehensive prognostic system","volume":"88","author":"Atzpodien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2011.09.008_bib31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00002371-200309000-00002","article-title":"Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapy","volume":"26","author":"Fumaqalli","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.urolonc.2011.09.008_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.annonc.a058239","article-title":"Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2","volume":"3","author":"Palmer","year":"1992","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911003127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143911003127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:12:03Z","timestamp":1786450323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143911003127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1078143911003127"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.09.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significant immunological characteristics of peripheral blood neutrophil-to-lymphocyte ratio and Fas ligand expression incidence in nephrectomized tumor in late recurrence from renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2011.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}